Tempus AI (NASDAQ:TEM) Shares Gap Up – Should You Buy?

Tempus AI, Inc. (NASDAQ:TEM)’s share price gapped up prior to trading on Friday . The stock had previously closed at $35.29, but opened at $36.92. Tempus AI shares last traded at $37.10, with a volume of 1,362,172 shares changing hands.

Analysts Set New Price Targets

A number of equities research analysts have commented on TEM shares. Bank of America increased their price objective on shares of Tempus AI from $52.00 to $54.00 and gave the stock a “neutral” rating in a report on Friday, December 13th. Wolfe Research initiated coverage on shares of Tempus AI in a report on Friday, December 13th. They issued an “outperform” rating and a $60.00 price target for the company. Piper Sandler reaffirmed a “neutral” rating and set a $70.00 price objective (up previously from $40.00) on shares of Tempus AI in a report on Tuesday, November 12th. Loop Capital lifted their target price on Tempus AI from $48.00 to $57.00 and gave the company a “buy” rating in a research note on Tuesday, October 15th. Finally, Stifel Nicolaus downgraded Tempus AI from a “buy” rating to a “hold” rating and boosted their target price for the stock from $45.00 to $65.00 in a research report on Monday, November 11th. Three investment analysts have rated the stock with a hold rating and nine have given a buy rating to the company. Based on data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and an average price target of $56.00.

Tempus AI Trading Up 1.7 %

The business has a fifty day moving average price of $50.34. The company has a quick ratio of 2.55, a current ratio of 2.69 and a debt-to-equity ratio of 8.17.

Insider Buying and Selling

In other news, CEO Eric P. Lefkofsky sold 187,655 shares of Tempus AI stock in a transaction dated Wednesday, December 18th. The stock was sold at an average price of $37.54, for a total transaction of $7,044,568.70. Following the transaction, the chief executive officer now owns 9,557,283 shares in the company, valued at $358,780,403.82. The trade was a 1.93 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, major shareholder Bradley A. Keywell sold 395,800 shares of the business’s stock in a transaction that occurred on Wednesday, December 11th. The shares were sold at an average price of $42.95, for a total value of $16,999,610.00. Following the completion of the transaction, the insider now owns 16,164,449 shares of the company’s stock, valued at $694,263,084.55. This represents a 2.39 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 845,041 shares of company stock valued at $35,125,473 in the last 90 days.

Institutional Inflows and Outflows

A number of institutional investors have recently bought and sold shares of TEM. Kovitz Investment Group Partners LLC acquired a new position in shares of Tempus AI during the third quarter worth about $1,367,000. Sumitomo Mitsui Trust Group Inc. boosted its position in Tempus AI by 1,591.2% during the 3rd quarter. Sumitomo Mitsui Trust Group Inc. now owns 1,217,699 shares of the company’s stock worth $68,922,000 after acquiring an additional 1,145,698 shares during the last quarter. Captrust Financial Advisors acquired a new position in Tempus AI during the 3rd quarter worth approximately $2,726,000. Sigma Planning Corp bought a new position in shares of Tempus AI during the 3rd quarter worth approximately $1,323,000. Finally, Dakota Wealth Management acquired a new stake in shares of Tempus AI in the third quarter valued at approximately $1,185,000. Institutional investors own 24.22% of the company’s stock.

About Tempus AI

Tempus AI Inc is a technology company advancing precision medicine through the practical application of artificial intelligence principally in healthcare. The company provides AI-enabled precision medicine solutions to physicians to deliver personalized patient care and in parallel facilitates discovery, development and delivery of optimal therapeutics.